Skip to main content
CTOS 2023 Main banner
Final Program


Schedule at a Glance
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back

Bone Sarcomas

(P 83) CLINICO-GENOMIC PROFILING OF CONVENTIONAL AND DEDIFFERENTIATED CHONDROSARCOMAS REVEALS TP53 MUTATION TO BE ASSOCIATED WITH WORSE OUTCOMES

Location: The Liffey, Level 1
Objective: Chondrosarcomas are the most common primary bone tumor in adults. IDH1 and IDH2 mutations are prevalent. We aimed to assess the clinico-genomic properties of IDH mutant versus IDH wild type (WT) chondrosarcomas as well as alterations in other genes.

Methods: We included 93 patients with conventional and dedifferentiated chondrosarcoma for which there was available clinical next generation sequencing data. Clinical and genomic data were extracted and compared between IDH mutant and IDH WT chondrosarcomas and between TP53 mutant and TP53 WT chondrosarcomas.

Results: As expected, tumor grade was a strong predictor of survival. IDH1 and IDH2 mutations are prevalent in chondrosarcoma (50.5%), more common in chondrosarcomas arising in the extremities, associated with higher age at diagnosis, and more common in dedifferentiated chondrosarcomas compared to grades 1-3 conventional chondrosarcoma. There was no difference in survival based on IDH mutation in univariate and multivariate analyses. TP53 mutation was the next most prevalent (41.9%) and is associated with worse overall survival and metastasis-free survival in both univariate and multivariate analyses (figure). A personal history of other cancers was seen in 17.2% of chondrosarcoma patients.

Conclusion: IDH mutations are prevalent in chondrosarcoma though were not associated with survival outcomes in this cohort. TP53 mutations were the next most common alteration and were associated with worse outcomes.